Page 83 - BH-2-3

Brain & Heart Lipids in ALS: Bad and beneficial

Deoxycholic acid has not been extensively studied in Author contributions
ALS, but its derivative, tauroursodeoxycholic acid, has
been found promising against ALS. Research suggests Conceptualization: Toluwase Hezekiah Fatoki
66
that dysregulation of bile acids, such as deoxycholic Formal analysis: All authors
acid produced by gut microbiota, plays a key role in the Investigation: All authors
pathogenesis of neurodegenerative diseases. 67 Methodology: Toluwase Hezekiah Fatoki
Visualization: Toluwase Hezekiah Fatoki, Tosin Christianah
Molecular docking and MDS play crucial roles in Balogun, Oyeleke Ridwan Oyebiyi, Samuel Oluwaseun
predicting ligand binding sites and evaluating protein- Ogunleye
ligand complex stability, providing insights into their Writing – original draft: All authors
interactions and potential therapeutic efficacy. 23,68 A Writing – review & editing: Toluwase Hezekiah Fatoki,
binding affinity score of ≤−5.00 kcal/mol indicates Ibrahim Olabayode Saliu
69
good ligand-protein interaction. RMSD values >7
Å indicate suggest high flexibility, less compactness, Ethics approval and consent to participate
and conformational divergence of protein structural Not applicable.
ensembles during simulation. These computational
23
methods, along with prime MMGBSA analysis, contribute Consent for publication
to understanding the energetics of ligand-receptor
interactions. 23,68 Not applicable.
5. Conclusion Availability of data
This study has identified several lipid-based compounds Data are available from the corresponding author on
that exhibit varying effects on ALS pathology. Among reasonable request.
these compounds, four were found to permeate the BBB: References
Two displayed therapeutic potential (resveratrol and
valproic acid), while the other two were associated with 1. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis.
detrimental effects (4-hydroxynonenal and rotenone). N Engl J Med. 2001;344:1688-1700.
Further investigation is warranted to explore the synergistic doi: 10.1056/NEJM200105313442207
effects of resveratrol and valproic acid in ALS treatment, 2. Yáñez M, Galán L, Matías-Guiu J, Vela A, Guerrero A,
elucidate the mechanisms underlying 4-hydroxynonenal García AG. CSF from amyotrophic lateral sclerosis patients
involvement in the formation of enzyme aggregate produces glutamate independent death of rat motor brain
in ALS, and assess the potential impact of long-term cortical neurons: Protection by resveratrol but not riluzole.
human exposure to rotenone from marine food on ALS Brain Res. 2011;1423:77-86.
development. These avenues of research could provide doi: 10.1016/j.brainres.2011.09.025
valuable insights into ALS pathogenesis and facilitate
the development of effective therapeutic interventions. 3. Saez-Atienzar S, Bandres-Ciga S, Langston RG,
Moreover, our future research endeavors will prioritize et al. Genetic analysis of amyotrophic lateral sclerosis
classifying potential contributors to ALS, including genetic identifies contributing pathways and cell types. Sci Adv.
2021;7(3):eabd9036.
factors, environmental toxicity, and autoimmune diseases
that target the nervous system, potentially leading to motor doi: 10.1126/sciadv.abd9036
neuron damage. This classification could provide valuable 4. Fatoki TH, Chukwuejim S, Udenigwe CC, Aluko RE. In silico
insights into disease etiology and guide personalized exploration of metabolically active peptides as potential
treatment approaches. therapeutic agents against amyotrophic lateral sclerosis. Int J
Mol Sci. 2023;24(6):5828.
Acknowledgments
doi: 10.3390/ijms24065828
None. 5. Gyawali A, Latif S, Choi SH, Hyeon SJ, Ryu H, Kang YS.

Funding Monocarboxylate transporter functions and neuroprotective
effects of valproic acid in experimental models of
None. amyotrophic lateral sclerosis. J Biomed Sci. 2022;29:2.
doi: 10.1186/s12929-022-00785-3
Conflict of interest
6. Desport JC, Preux PM, Magy L, et al. Factors correlated
The authors declare that they have no competing interests. with hypermetabolism in patients with amyotrophic lateral

Volume 2 Issue 3 (2024) 12 doi: 10.36922/bh.2976